The price of NAHDI stock is one of the most discussed topics among investors and followers of the Saudi financial market, especially after the listing of NAHDI Medical Company on the main market in March 2023. In this article, we will comprehensively review the price of NAHDI stock and analyze its performance in the market during 2024 and 2025, relying on the latest financial data and official disclosures. NAHDI Medical represents one of the largest pharmacy chains in the Kingdom of Saudi Arabia and plays a pivotal role in the pharmaceutical retail sector. Several factors have contributed to shaping the dynamics of NAHDI's stock price, including the growth of healthcare spending, the development of government policies such as mandatory health insurance, and continuous innovation in health services. Furthermore, the company's quarterly results, expansion strategies, and regulatory changes in the healthcare sector affect the stock's attractiveness to investors. This article will present details of the key financial indicators for NAHDI stock, discuss operational strategies, and highlight major competitors in the market, along with the latest news and developments. Committed to the rules of the Capital Market Authority, we present this analysis in an educational and neutral language without any investment recommendations, emphasizing the importance of consulting a licensed financial advisor before making any investment decisions.
Overview of NAHDI Medical Company and Its Listing History
NAHDI Medical Company was established in the mid-1980s and has achieved significant growth to become the largest pharmacy chain in the Kingdom of Saudi Arabia today. NAHDI branches are spread across various regions, offering a wide range of medications, medical supplies, and healthcare products. The company is distinguished by its ability to expand rapidly and adopt the latest technologies in the medical retail sector. NAHDI entered the Saudi financial market (Tadawul) through an initial public offering in March 2023, with its stock trading under the symbol NAHDI in the main market. The IPO saw interest from local and international institutions, including the Public Investment Fund and Walgreens Boots, enhancing its position as a leading company in the sector. Since its listing, NAHDI has played a pivotal role in developing the Saudi pharmaceutical sector, leading in terms of branch size, revenue, and geographical expansion.
NAHDI Stock Price Evolution Since Listing
Since its listing in March 2023, NAHDI's stock price has experienced moderate fluctuations reflecting market reactions to the company's results and developments in the healthcare sector. Between 2024 and 2025, the stock price ranged between approximately 90 and 100 Saudi Riyals. This range reflects a balance between investor confidence in the company's growth and seasonal market influences. The stock features moderate liquidity, with an average daily trading volume of hundreds of thousands of shares. This reflects the interest of individual and institutional investors in NAHDI stock, granting it relative stability compared to some other stocks in the same sector. It is important to recognize that the stock price is influenced by internal factors such as financial results and distributions, as well as external factors like government policies and overall market movements.
Market Capitalization, Liquidity, and Capital Size
The market capitalization of NAHDI Medical Company ranged between 12 and 13 billion Saudi Riyals during 2024 and 2025, based on an issued share count of approximately 130 million shares. This large size positions NAHDI among the leading companies in the medical retail sector in the Saudi market. The relatively high liquidity of the stock reflects investor confidence and institutional presence in NAHDI trading, facilitating investors' entry and exit from the stock without significantly impacting the price. Liquidity is a crucial factor in assessing the risks and opportunities associated with investing in any stock, as it reduces the likelihood of unexpected fluctuations when executing large buy or sell orders.
Price-to-Earnings (P/E) Ratio and NAHDI Stock Profitability Analysis
The price-to-earnings (P/E) ratio is one of the most important indicators used in stock valuation. In 2024, NAHDI's P/E ratio was approximately between 22 and 25 times, based on a stock price close to 100 Riyals and an annual earnings per share exceeding 4 Riyals. This ratio falls within the normal range for companies in the medical and retail sectors in the Kingdom, reflecting market expectations for sustainable growth in the company's profits. It should be noted that the P/E ratio changes with quarterly and annual results and overall market performance. This indicator serves as a tool for comparing the stock with its peers in the sector, but it should not be relied upon solely in evaluating investment opportunities or risks.
Cash Dividends and NAHDI's Dividend Policy
NAHDI has maintained a regular cash dividend policy since its listing. In 2024, the board of directors approved a dividend distribution of 300 million Riyals for the second half of the year, equivalent to 3 Riyals per share. These distributions represent about 30% of the company's capital. The average cash yield per share ranged between 4% and 6% annually, depending on stock price fluctuations. This policy indicates the company's desire to achieve a balance between reinvesting profits for business expansion and rewarding shareholders. The value of distributions changes with annual profits and the company's need to finance its expansion plans.
Recent Financial Results: Revenue and Net Profit
NAHDI's financial results in 2024 showed significant revenue growth, reaching 9.44 billion Saudi Riyals, an increase of 8.4% compared to 2023. The annual net profit was approximately 550–600 million Riyals, reflecting stability in performance despite some pressure on profit margins due to rising operational costs. In the fourth quarter of 2024 specifically, the company recorded a net profit of 157.90 million Riyals, with quarterly revenues of 2.36 billion Riyals. Despite a slight decline in net profit compared to previous quarters, revenues continued to rise, supported by increased demand for pharmaceutical products and primary health services.
Factors Influencing NAHDI Stock Price in the Market
The price of NAHDI stock is influenced by several key factors. Among the most prominent are the company's financial performance, where revenue results and net profit play a pivotal role in driving the stock price. Regular cash distributions increase the stock's attractiveness to investors seeking stable returns. Government policies and regulatory changes, such as mandatory health insurance and drug price controls, affect the company's profit margins. Additionally, the company's initiatives for geographical expansion and digital service innovation enhance investor confidence. The overall economic situation, interest rates, and the general movement of the Saudi market also impact NAHDI's stock movement.
Analysis of the Pharmaceutical Retail Sector and Major Competitors
NAHDI operates within the pharmaceutical and health retail sector in Saudi Arabia, a sector experiencing annual growth driven by increased healthcare spending and population growth. Major local competitors include Al-Dawaa Pharmacies, which rival NAHDI in branch size and sales, along with smaller chains like Danube Pharmacy and Al-Nas Pharmacy. NAHDI also faces increasing competition from e-commerce platforms and medical applications that allow for online ordering and home delivery of medications. However, NAHDI maintains a significant market share, reaching around 70% of total local pharmacy sales when combined with Al-Dawaa Pharmacies. NAHDI's operational expertise, geographical reach, and brand strength allow it to maintain its leading position in the sector.
Expansion and Development Strategies at NAHDI
NAHDI has adopted an active expansion strategy in recent years, including the opening of new branches both domestically and internationally. The company focuses on diversifying products and introducing digital services such as telemedicine consultations and home delivery. It has also formed strategic partnerships with global health and technology companies, notably Walgreens Boots. Through these initiatives, NAHDI aims to enhance its competitiveness and meet the needs of a larger customer segment. Additionally, the company has invested in developing digital sales channels and responding to the requirements of digital transformation in the pharmacy sector. These steps affirm NAHDI's commitment to keeping pace with technological developments and improving operational efficiency.
The Role of Strategic Partners and Institutional Support
One of the factors contributing to NAHDI Medical's strength is its support from major institutions such as the Saudi Public Investment Fund and Walgreens Boots. This support provides global expertise in pharmacy management and strong financing that enables the company to implement its expansion plans smoothly. Collaborating with these institutions allows NAHDI to benefit from best practices in supply chain management, product development, and customer experience enhancement. Institutional support also boosts investor confidence in the company's long-term sustainability and provides it with greater capacity to face market challenges and regulatory changes.
Regulatory and Legislative Impacts on NAHDI's Operations
The healthcare and pharmaceutical sector in Saudi Arabia has recently witnessed significant regulatory updates, including the electronic registration of all transactions linked to the patient's health record. These regulations require pharmacy companies to adapt to digital transformation requirements and enhance transparency. For NAHDI, these developments may present opportunities to enhance operational efficiency, but they also require additional investments in technical infrastructure and training. Drug price controls and regulatory oversight affect profit margins; however, expanding sales and diversifying products can sometimes compensate for lower margins. NAHDI's ability to quickly adapt to regulatory changes emerges as a strength in maintaining its competitiveness.
Future Risks and Opportunities for NAHDI Stock
Like all stocks in the financial market, NAHDI stock faces a range of risks and opportunities. Among the most significant risks are market volatility, sudden regulatory changes, and price pressures on pharmaceutical products. Opportunities lie in the continuous growth of the healthcare sector, increased demand for medical services, and the company's expansion into digital sales channels. NAHDI's financial flexibility, high liquidity, and branch distribution allow it to successfully face challenges. Additionally, adopting technology and innovation in providing health services offers the company a competitive edge in the Saudi and regional markets.
Recent News and Developments Regarding NAHDI Stock
In March 2025, NAHDI announced strong financial results for 2024, with annual revenue growth and stable cash dividends. The company continued to implement expansion plans and open new branches, alongside launching innovative health and digital services. It also strengthened its partnerships with leading global and local institutions, positively reflecting on investor confidence. In the sector, the Saudi market continues to support the healthcare and pharmacy sector through initiatives under 'Vision 2030' and national transformation programs. NAHDI stands out as one of the companies most benefiting from these initiatives, enhancing its position in the market in the medium and long term.
Conclusion
In conclusion, the price of NAHDI stock reflects the dynamics and evolution of the pharmaceutical retail sector in the Kingdom of Saudi Arabia. Thanks to strong financial performance, regular distribution policies, and continuous expansion, NAHDI has succeeded in maintaining its leading position while achieving sustainable revenue growth rates. However, the stock is subject to various influences, including regulatory changes, economic fluctuations, and increasing competition from digital channels. It is essential for any investor or interested party monitoring NAHDI's stock price to rely on accurate financial analysis and continuously follow official disclosures and sector developments. The SIGMIX platform is committed to providing educational and neutral content on the concepts and performance of Saudi stocks, emphasizing the necessity of consulting a licensed financial advisor before making any investment decisions to ensure achieving your financial goals safely and efficiently.
Frequently Asked Questions
The trading symbol for NAHDI Medical Company in the Saudi financial market is NAHDI. The stock's performance can be monitored daily through the Saudi Tadawul platform (main market) and economic news websites that provide real-time updates on price, trading volume, and financial indicators. NAHDI's official website also offers disclosure data and periodic reports for investors.
NAHDI's stock price is trading between approximately 90 and 100 Saudi Riyals during the period of 2024-2025, depending on market conditions and the company's quarterly results. Based on the number of issued shares (approximately 130 million shares), the company's market capitalization ranges between 12 and 13 billion Saudi Riyals, making it one of the largest pharmaceutical retail companies in the Kingdom.
The price-to-earnings (P/E) ratio is calculated by dividing the market price per share by the annual earnings per share (EPS). In NAHDI's case for 2024, the stock price was around 100 Riyals and the earnings per share was about 4 Riyals, making the P/E ratio approximately 25 times. This indicator helps investors compare the stock with shares of similar companies in the sector, but it should not be the sole indicator for making an investment decision.
Yes, NAHDI has been distributing regular cash dividends since its listing in the financial market. In 2024, the company distributed dividends of 3 Riyals per share for the second half of the year, equating to an annual yield ranging between 4% and 6% depending on the stock price at the time of distribution. The value of distributions changes based on annual profitability and the company's policy in allocating profits between expansion and shareholder payments.
The movement of NAHDI's stock price is influenced by several factors, the most important of which are: the company's quarterly and annual financial results, cash distribution policies, legislative changes (such as price controls and health insurance), digital and geographical expansion initiatives, as well as the general economic conditions in the Kingdom. Competition in the pharmacy sector and innovation in digital services also play an increasingly important role in determining the stock's attractiveness.
NAHDI faces strong competition from Al-Dawaa Pharmacies, which is considered the largest or second largest in the Kingdom in terms of the number of branches and sales. It is also challenged by smaller chains such as Danube Pharmacy and Al-Nas Pharmacies, in addition to independent pharmacies and distribution companies. Recently, competition has emerged from online platforms and medical applications that offer medication delivery services to patients via the internet.
Yes, NAHDI has an active expansion strategy that includes opening new branches within and outside Saudi Arabia, and developing digital services such as medical consultations and electronic delivery. The company has also formed strategic partnerships with global health and technology companies and seeks to enhance its operations in primary healthcare services and innovative health products within its branches.
Among the most significant risks are: sudden changes in regulatory policies or price controls, rising operational costs, intense competition from large chains and digital applications, and general economic fluctuations. However, NAHDI enjoys strong cash liquidity and operational flexibility that help it withstand many of these challenges, especially due to its geographical spread and brand strength.
Regulatory updates, such as electronic transaction registration and linking them to health records, impose challenges on pharmacy companies in terms of investment in technology and training. However, these developments can enhance operational efficiency and improve customer experience. The ability to quickly adapt to new regulations is one of the key elements of NAHDI's success and its ability to maintain its leading position.
Strategic partners such as the Public Investment Fund and Walgreens Boots provide NAHDI with financial support and global expertise in pharmacy management and supply chains. This support enhances NAHDI's ability to implement expansion plans and boosts investor confidence in the company's sustainability and financial strength over the long term.
Analysts' expectations for NAHDI stock range from neutral to positive, as stable financial performance and continuous expansion indicate the likelihood of ongoing growth. However, the stock's movement remains contingent on market developments, future financial performance, and competitive impacts. It is always advisable to consult a licensed financial advisor before making any investment decisions in stocks.
Consulting a licensed financial advisor is essential to understand the nature of the risks associated with NAHDI stock or any other stock and to determine its suitability for your personal financial goals. Professional consultation helps build a balanced investment strategy, provides accurate analysis of market influencing factors, and avoids making ill-considered investment decisions that could negatively impact your financial portfolio.